Post-translational modifications of protein biopharmaceuticals.
about
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational ModificationsFc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsEarly implementation of QbD in biopharmaceutical development: a practical examplePlant-based solutions for veterinary immunotherapeutics and prophylacticsRecent advances in mammalian protein productionSparse labeling of proteins: structural characterization from long range constraintsEngineering Translation in Mammalian Cell Factories to Increase Protein Yield: The Unexpected Use of Long Non-Coding SINEUP RNAsDevelopments in the tools and methodologies of synthetic biologyIndependent highly sensitive characterization of asparagine deamidation and aspartic acid isomerization by sheathless CZE-ESI-MS/MS.The role of Periodic Safety Update Reports in the safety management of biopharmaceuticals.Glycosylation and disulfide bond analysis of transiently and stably expressed clade C HIV-1 gp140 trimers in 293T cells identifies disulfide heterogeneity present in both proteins and differences in O-linked glycosylationThe GalNAc-type O-Glycoproteome of CHO cells characterized by the SimpleCell strategyExpression of the functional recombinant human glycosyltransferase GalNAcT2 in Escherichia coliDetoxifying Escherichia coli for endotoxin-free production of recombinant proteins.Isolation and Characterization of Acetylated Derivative of Recombinant Insulin Lispro Produced in Escherichia coliPeptide identification by tandem mass spectrometry with alternate fragmentation modes.Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodiesEstablishment of a CpG island microarray for analyses of genome-wide DNA methylation in Chinese hamster ovary cells.Transduction of human recombinant proteins into mitochondria as a protein therapeutic approach for mitochondrial disorders.Increasing recombinant protein production in Escherichia coli through metabolic and genetic engineering.Post-genomics of bone metabolic dysfunctions and neoplasias.Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach.Prospects in the total synthesis of protein therapeutics.Host cell protein analysis in therapeutic protein bioprocessing - methods and applications.New opportunities by synthetic biology for biopharmaceutical production in Pichia pastoris.Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.Assessment of the metabolism of therapeutic proteins and antibodies.Protein folding and secretion: mechanistic insights advancing recombinant protein production in S. cerevisiae.Glyco-engineering for biopharmaceutical production in moss bioreactors.Structural identification of modified amino acids on the interface between EPO and its receptor from EPO BRP, human recombinant erythropoietin by LC/MS analysis.Laboratory Scale Production and Purification of a Therapeutic Antibody.Recombinant Structural Proteins and Their Use in Future Materials.Functional expression of the human coagulation factor IX using heterologous signal peptide and propeptide sequences in mammalian cell line.Transient expression of rabies virus G-glycoprotein using BHK-21 cells cultured in suspension.Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications.Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins.Generation of a Chinese hamster ovary cell line producing recombinant human glucocerebrosidase.A theoretical estimate for nucleotide sugar demand towards Chinese Hamster Ovary cellular glycosylation.Expression of granulocyte colony stimulating factor (GCSF) in Hansenula polymorpha.Pichia pastoris Mut(S) strains are prone to misincorporation of O-methyl-L-homoserine at methionine residues when methanol is used as the sole carbon source.
P2860
Q26738810-F38933A1-AC31-4757-B7DD-F102F228BC1AQ26822421-7F5962FC-DC0B-4F93-B266-8B82CBD53B26Q26830466-A14A5B6E-B9B9-4A2D-9F2B-68754C75AFB5Q27000876-695F54A2-BD41-4C78-AB9F-795C809CFEB6Q27008285-CB737432-9162-4AC4-AA19-56FE0225C422Q27014556-2A8B8B4D-B0F0-4C24-BAC7-A9486635B63AQ28071440-6C2AD011-47B1-488A-B28F-36707EB59A7EQ28651359-73DF61A4-B033-4E27-9974-177FE33D5CDFQ30384596-9B3D83AE-3C4F-4777-ABC7-4B19FFC0D02CQ30394388-C0D67A42-B1E3-4319-A43B-7FAB0EDCCD9CQ34141693-5EA731AF-A060-4A83-B872-6B6D5B6F98BEQ34634855-A52FE68D-9B67-4AD8-ADE6-6FB28517DD43Q34987860-717271B1-14C7-4658-8CC0-67E24FA64DF1Q35503548-53FF6CBC-2AFF-4A8E-9BEE-CBFFCC0DB517Q35558005-1CACB8E8-693C-4B02-AAB3-7945E3434746Q36211835-B0B78F97-6692-40D2-BC3B-DBE02E134E02Q36910611-322CF5FC-60F3-442B-851F-10FB06CE3DF3Q37474026-CB975BC6-0AB2-4E6E-A405-914EB06A417FQ37923355-034C1E38-E723-4FFC-9C07-D3A799312A07Q37928986-BBF1175D-F81D-466A-9418-D0E9864F9DFFQ37975963-1F3297BE-B6F6-49ED-98C5-827D7FF699ECQ37999739-3FBBB371-89C1-4973-8429-536C34621172Q38068570-31A1958F-5AF3-4F6F-8BDE-CCA1E15D1678Q38084258-B2EA1066-769A-49E8-BF29-C283644C0DD4Q38092339-370C8C66-82E4-4917-8EB1-C7CB89964C9BQ38127745-0D7F4AEF-0BA0-422C-8BDB-2DA48AA4CA2AQ38217623-C1802C35-3667-43DC-9134-CCC349537CEFQ38230560-01127B71-297D-4334-94D9-611EE4578380Q38234961-1137B712-45A6-4D4B-8136-6C495A855CF2Q38433394-09CC5B0E-B18F-462C-9BB8-005B3117ED28Q38716755-B2FDBF16-F87F-424D-ACAD-03A335123207Q38768666-E1A7DA33-3E2B-4E58-B05F-414B1D271DEDQ38860655-A4B72F1C-777A-4275-A8AF-92846D9136AFQ38907732-A432CE4B-1D0C-4CDD-AF62-287BA5DE4026Q39149359-98550765-7787-462B-BF24-827DDC255151Q39206787-30ACFF4B-13A2-42E1-8894-5D3BBA552CB7Q39254681-8386A0BB-C783-41D3-A893-99E8B18E7D3DQ39654089-4AE53D1C-BA75-439E-B572-B77F8C5D23ECQ40244997-05616917-115B-4338-AC60-29628FF9D088Q42575421-64025490-93D9-479B-9AC3-08A73BC15AA9
P2860
Post-translational modifications of protein biopharmaceuticals.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Post-translational modifications of protein biopharmaceuticals.
@en
Post-translational modifications of protein biopharmaceuticals.
@nl
type
label
Post-translational modifications of protein biopharmaceuticals.
@en
Post-translational modifications of protein biopharmaceuticals.
@nl
prefLabel
Post-translational modifications of protein biopharmaceuticals.
@en
Post-translational modifications of protein biopharmaceuticals.
@nl
P1433
P1476
Post-translational modifications of protein biopharmaceuticals.
@en
P2093
Gary Walsh
P304
P356
10.1016/J.DRUDIS.2010.06.009
P577
2010-06-25T00:00:00Z